Proteomic Analysis of Melanomas Identifies Biomarkers for Metastasis
Author Information
Author(s): Huang Sharon K., Darfler Marlene M., Nicholl Michael B., You Jinsam, Bemis Kerry G., Tegeler Tony J., Wang Mu, Wery Jean-Pierre, Chong Kelly K., Nguyen Linhda, Scolyer Richard A., Hoon Dave S. B.
Primary Institution: John Wayne Cancer Institute at Saint John's Health Center
Hypothesis
To identify potential biomarkers associated with melanoma progression and metastasis through proteomic analysis.
Conclusion
The study identified several proteins that are differentially expressed in metastatic melanomas compared to primary melanomas, suggesting their potential as biomarkers for tumor progression.
Supporting Evidence
- The study identified 120 significant changes in protein levels between metastatic and primary melanomas.
- Over 1500 proteins were identified in the tissue lysates with a peptide ID confidence level of >75%.
- The methodology successfully extracted proteins from microdissected FFPE tissues for analysis.
Takeaway
Researchers looked at melanoma samples to find proteins that change when the cancer spreads, helping to identify markers that could predict how the disease progresses.
Methodology
The study used LC/MS-based label-free protein quantification to analyze proteins from microdissected formalin-fixed paraffin-embedded melanoma tissues.
Potential Biases
Potential biases may arise from the variability in tissue preparation and the retrospective analysis of archived samples.
Limitations
The study's findings may be limited by the retrospective nature of the tissue samples and the challenges in protein extraction from FFPE tissues.
Participant Demographics
The study analyzed archival melanoma tissues without specific demographic details provided.
Statistical Information
P-Value
q<0.05
Statistical Significance
q<0.05
Digital Object Identifier (DOI)
Want to read the original?
Access the complete publication on the publisher's website